Literature DB >> 7550237

Detection of sequence variants in the gene encoding the beta 3 chain of laminin 5 (LAMB3).

L Pulkkinen1, J A McGrath, A M Christiano, J Uitto.   

Abstract

Laminin 5, a candidate gene/protein system for mutations in the junctional forms of epidermolysis bullosa (JEB), consists of three polypeptides encoded by the LAMA3, LAMB3, and LAMC2 genes. In this study, primer pairs for the amplification of the complete cDNA as well as 22 exons of the LAMB3 gene encoding the entire beta 3 chain of laminin 5, were established. The primers for amplification of individual exons from genomic DNA were placed at least 50 bp away from the exon-intron borders in the flanking intronic sequences. For amplification of cDNA generated by RT-PCR, eight primer pairs covering overlapping segments of mRNA were used. The amplified sequences were used to study sequence variations of the LAMB3 gene in patients with JEB and unrelated individuals using heteroduplex analysis. Nine out of 13 JEB patients examined showed heteroduplexes in at least one of the PCR products, indicating the existence of two variable alleles in their DNA. Sequence analyses revealed putative pathogenetic mutations in seven of the JEB patients, while four of the heteroduplexes resulted from polymorphisms, reflecting a single basepair substitution. The results demonstrate that this method is useful in the detection of JEB mutations, as well as polymorphisms in the LAMB3 gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550237     DOI: 10.1002/humu.1380060115

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Maternal uniparental disomy of chromosome 1 with reduction to homozygosity of the LAMB3 locus in a patient with Herlitz junctional epidermolysis bullosa.

Authors:  L Pulkkinen; F Bullrich; P Czarnecki; L Weiss; J Uitto
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

2.  Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease.

Authors:  Christiane Mühle; Qiu-Jie Jiang; Alexandra Charlesworth; Leena Bruckner-Tuderman; Guerrino Meneguzzi; Holm Schneider
Journal:  Hum Genet       Date:  2004-11-05       Impact factor: 4.132

3.  Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants.

Authors:  R Varki; S Sadowski; E Pfendner; J Uitto
Journal:  J Med Genet       Date:  2006-02-10       Impact factor: 6.318

4.  A preliminary gene map for the Van der Woude syndrome critical region derived from 900 kb of genomic sequence at 1q32-q41.

Authors:  B C Schutte; B C Bjork; K B Coppage; M I Malik; S G Gregory; D J Scott; L M Brentzell; Y Watanabe; M J Dixon; J C Murray
Journal:  Genome Res       Date:  2000-01       Impact factor: 9.043

5.  Expression of Laminin 332 in Vesicant Skin Injury and Wound Repair.

Authors:  Yoke-Chen Chang; Marion K Gordon; Donald R Gerecke
Journal:  Clin Dermatol (Wilmington)       Date:  2018

Review 6.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

Review 7.  Molecular complexity of the cutaneous basement membrane zone.

Authors:  J Uitto; L Pulkkinen
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

8.  Detection of novel LAMC2 mutations in Herlitz junctional epidermolysis Bullosa.

Authors:  L Pulkkinen; J McGrath; T Airenne; H Haakana; K Tryggvason; S Kivirikko; G Meneguzzi; J P Ortonne; A M Christiano; J Uitto
Journal:  Mol Med       Date:  1997-02       Impact factor: 6.354

Review 9.  Defining the role of laminin-332 in carcinoma.

Authors:  Cherise M Guess; Vito Quaranta
Journal:  Matrix Biol       Date:  2009-08-15       Impact factor: 11.583

10.  Laminin 5 binds the NC-1 domain of type VII collagen.

Authors:  P Rousselle; D R Keene; F Ruggiero; M F Champliaud; M Rest; R E Burgeson
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.